Eupraxia Pharmaceuticals (EPRX)
Market Price (10/23/2026): $7.61 | Market Cap: $498.3 MilSector: Health Care | Industry: Biotechnology
Eupraxia Pharmaceuticals (EPRX)
Market Price (10/23/2026): $7.61Market Cap: $498.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -27% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Chronic Pain Management, and Targeted Therapies. | Weak multi-year price returns3Y Excs Rtn is -6.5% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.07, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -57 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% Key risksEPRX key risks include [1] its dependence on external financing as a pre-revenue company and [2] uncertain market adoption of its proprietary DiffuSphere™ delivery technology. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -27% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Chronic Pain Management, and Targeted Therapies. |
| Weak multi-year price returns3Y Excs Rtn is -6.5% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.07, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -57 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% |
| Key risksEPRX key risks include [1] its dependence on external financing as a pre-revenue company and [2] uncertain market adoption of its proprietary DiffuSphere™ delivery technology. |
Qualitative Assessment
AI Analysis | Feedback
Eupraxia Pharmaceuticals (EPRX) stock has gained about 15% since 6/30/2026 because of the following key factors:
1. Continued Positive Clinical Trial Outcomes for EP-104GI in Eosinophilic Esophagitis (EoE).
Eupraxia Pharmaceuticals reported significant positive data from its Phase 1b/2a RESOLVE trial for EP-104GI in the treatment of EoE during fiscal Q3 2026. On August 13, 2026, the company announced a reduction in moderate to severe odynophagia (painful swallowing) from 62% at baseline to 25% at 24 and 52 weeks post-treatment in specific cohorts, with no patients experiencing severe odynophagia. This was followed by an update on September 30, 2026, showcasing durable clinical remission in 64% of patients for 52 weeks after a single administration of EP-104GI in the highest dose cohorts, alongside meaningful histologic improvements. The successful enrollment of 120 patients in the Phase 2b portion of the RESOLVE trial on October 12, 2026, with interim data anticipated in December 2026, further solidified investor confidence by demonstrating continued progress and a favorable safety profile with over 3,000 injections administered without treatment-related serious adverse events.
2. Strong Analyst Endorsements and Elevated Price Targets.
Throughout fiscal Q3 2026 and early fiscal Q4 2026, Eupraxia Pharmaceuticals received consistently positive analyst ratings and price target affirmations. Oppenheimer, for instance, reiterated an Outperform rating and a $17.00 price target on October 20, 2026, indicating a potential upside exceeding 120% from the stock's then-current trading price of $7.66. Similarly, Cantor Fitzgerald maintained an Overweight rating with a $19.00 price target on October 7, 2026. The prevailing analyst consensus is a "Strong Buy," with an average price target of $16.35, suggesting a substantial potential increase of 146.23% from the current price. These endorsements reflect strong professional confidence in the company's clinical pipeline and future market potential.
Show more
Eupraxia Pharmaceuticals (EPRX) stock has gained about 15% since 6/30/2026 because of the following key factors:
1. Continued Positive Clinical Trial Outcomes for EP-104GI in Eosinophilic Esophagitis (EoE).
Eupraxia Pharmaceuticals reported significant positive data from its Phase 1b/2a RESOLVE trial for EP-104GI in the treatment of EoE during fiscal Q3 2026. On August 13, 2026, the company announced a reduction in moderate to severe odynophagia (painful swallowing) from 62% at baseline to 25% at 24 and 52 weeks post-treatment in specific cohorts, with no patients experiencing severe odynophagia. This was followed by an update on September 30, 2026, showcasing durable clinical remission in 64% of patients for 52 weeks after a single administration of EP-104GI in the highest dose cohorts, alongside meaningful histologic improvements. The successful enrollment of 120 patients in the Phase 2b portion of the RESOLVE trial on October 12, 2026, with interim data anticipated in December 2026, further solidified investor confidence by demonstrating continued progress and a favorable safety profile with over 3,000 injections administered without treatment-related serious adverse events.
2. Strong Analyst Endorsements and Elevated Price Targets.
Throughout fiscal Q3 2026 and early fiscal Q4 2026, Eupraxia Pharmaceuticals received consistently positive analyst ratings and price target affirmations. Oppenheimer, for instance, reiterated an Outperform rating and a $17.00 price target on October 20, 2026, indicating a potential upside exceeding 120% from the stock's then-current trading price of $7.66. Similarly, Cantor Fitzgerald maintained an Overweight rating with a $19.00 price target on October 7, 2026. The prevailing analyst consensus is a "Strong Buy," with an average price target of $16.35, suggesting a substantial potential increase of 146.23% from the current price. These endorsements reflect strong professional confidence in the company's clinical pipeline and future market potential.
3. Transfer to the Nasdaq Global Select Market.
On September 8, 2026, Eupraxia Pharmaceuticals completed its transfer to the Nasdaq Global Select Market. This move, occurring in fiscal Q3 2026, is generally perceived as a positive development for a company, as it increases visibility and trading liquidity by making the stock accessible to a wider pool of institutional and retail investors. This enhanced market presence and perceived stability likely contributed to the positive stock trend.
Show less
Stock Movement Drivers
Fundamental Drivers
The 14.8% change in EPRX stock from 6/30/2026 to 10/22/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302026 | 10222026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.61 | 7.59 | 14.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 57 | 65 | -13.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2026 to 10/22/2026| Return | Correlation | |
|---|---|---|
| EPRX | 14.8% | |
| Market (SPY) | 2.3% | 19.2% |
| Sector (XLV) | 14.3% | 6.9% |
Fundamental Drivers
The 4.8% change in EPRX stock from 3/31/2026 to 10/22/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312026 | 10222026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.24 | 7.59 | 4.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 51 | 65 | -21.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2026 to 10/22/2026| Return | Correlation | |
|---|---|---|
| EPRX | 4.8% | |
| Market (SPY) | 17.8% | 26.3% |
| Sector (XLV) | 24.2% | 10.4% |
Fundamental Drivers
The 28.6% change in EPRX stock from 9/30/2025 to 10/22/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302025 | 10222026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.90 | 7.59 | 28.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 36 | 65 | -45.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 10/22/2026| Return | Correlation | |
|---|---|---|
| EPRX | 28.6% | |
| Market (SPY) | 15.6% | 28.9% |
| Sector (XLV) | 31.9% | 8.5% |
Fundamental Drivers
The 37.5% change in EPRX stock from 9/30/2023 to 10/22/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302023 | 10222026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.52 | 7.59 | 37.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 22 | 65 | -66.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2023 to 10/22/2026| Return | Correlation | |
|---|---|---|
| EPRX | 37.5% | |
| Market (SPY) | 84.8% | 16.6% |
| Sector (XLV) | 47.5% | 10.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| EPRX Return | -18% | 17% | 55% | -24% | 138% | 2% | 177% |
| Peers Return | -15% | -20% | -11% | 0% | -35% | -43% | -77% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 104% |
Monthly Win Rates [3] | |||||||
| EPRX Win Rate | 40% | 17% | 42% | 33% | 50% | 40% | |
| Peers Win Rate | 46% | 31% | 44% | 47% | 47% | 26% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| EPRX Max Drawdown | - | -63% | -42% | -58% | -32% | -36% | |
| Peers Max Drawdown | -35% | -40% | -49% | -45% | -59% | -51% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, CMND, CNSY, CNXU, CSBR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/22/2026 (YTD)
How Low Can It Go
| Event | EPRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -12.9% | -18.8% |
| % Gain to Breakeven | 14.9% | 23.1% |
| Time to Breakeven | 17 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -14.3% | -7.8% |
| % Gain to Breakeven | 16.7% | 8.5% |
| Time to Breakeven | 43 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.6% | -9.5% |
| % Gain to Breakeven | 48.3% | 10.5% |
| Time to Breakeven | 692 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -34.0% | -24.5% |
| % Gain to Breakeven | 51.5% | 32.4% |
| Time to Breakeven | 126 days | 427 days |
In The Past
Eupraxia Pharmaceuticals's stock fell -12.9% during the 2025 US Tariff Shock. Such a loss loss requires a 14.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | EPRX | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.6% | -9.5% |
| % Gain to Breakeven | 48.3% | 10.5% |
| Time to Breakeven | 692 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -34.0% | -24.5% |
| % Gain to Breakeven | 51.5% | 32.4% |
| Time to Breakeven | 126 days | 427 days |
In The Past
Eupraxia Pharmaceuticals's stock fell -12.9% during the 2025 US Tariff Shock. Such a loss loss requires a 14.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Eupraxia Pharmaceuticals (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage biotechnology company focused on the discovery, development, and marketing of innovative technologies in the biotechnology sector. Headquartered in Victoria, Canada, the company's business model centers on advancing a pipeline of novel product candidates through clinical trials to address significant unmet medical needs across various disease areas.
The company's main product candidates are EP-104IAR, which is currently in a Phase III clinical trial for the treatment and pain relief associated with knee osteoarthritis. Another key candidate, EP-104GI, is in a Phase II clinical trial targeting eosinophilic esophagitis. Eupraxia also has EP-104 in preclinical studies for other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. Additionally, the company is actively developing product candidates within the oncology space.
Eupraxia Pharmaceuticals aims to serve patients globally who suffer from chronic and debilitating conditions. Its primary customer base includes individuals seeking relief from knee osteoarthritis pain, as well as those affected by eosinophilic esophagitis and various other inflammatory joint conditions. With its expansion into oncology, the company is also targeting the market for cancer treatments, positioning itself within the pharmaceutical sector focused on pain management, gastrointestinal disorders, inflammatory diseases, and cancer.
AI Analysis | Feedback
1. Think of it as an early-stage Amgen or Vertex Pharmaceuticals, intensely focused on developing new drugs for conditions like pain relief and inflammatory diseases, with its candidates currently in clinical trials.
2. It's an aspiring Regeneron Pharmaceuticals, with a pipeline of innovative drug candidates for conditions such as knee osteoarthritis and eosinophilic esophagitis, currently undergoing clinical trials.
3. A focused drug development company aiming for breakthroughs in specific disease areas like pain and inflammation, much like Vertex Pharmaceuticals became known for its work in cystic fibrosis, but currently with products in clinical trials.
AI Analysis | Feedback
- EP-104IAR: A product candidate in Phase III clinical trial for pain relief in knee osteoarthritis and other unmet medical needs.
- EP-104GI: A product candidate in Phase II clinical trial for the treatment of eosinophilic esophagitis.
- EP-104: A product candidate under preclinical studies for inflammatory joint conditions, benign structures of the esophagus, and epidural delivery.
- Oncology product candidates: Various product candidates currently under development for oncology.
AI Analysis | Feedback
Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage biotechnology company focused on the discovery, development, and marketing of drug candidates. As such, its lead product candidates are currently in various phases of clinical trials (Phase III, Phase II, and preclinical studies) and have not yet received regulatory approval for commercialization.
Therefore, Eupraxia Pharmaceuticals Inc. does not currently have major commercial customers, as its products are still under development and are not yet available for sale to other companies or individuals.
AI Analysis | Feedback
AI Analysis | Feedback
Dr. James A. Helliwell, M.D., Chief Executive Officer and Director
Dr. James A. Helliwell co-founded Eupraxia Pharmaceuticals Inc. in 2012. Before co-founding Eupraxia, he was a cardiothoracic anesthesiologist. He is also an angel investor in two startups.
Alexander Rothwell, Chief Financial Officer
Alexander Rothwell was re-appointed as Chief Financial Officer of Eupraxia Pharmaceuticals in February 2025, having previously served in the role from 2018-2021. He possesses over 25 years of experience in Canadian capital markets and investment banking, beginning his career in 1995 in institutional equities and merger arbitrage. His past leadership roles include President and Executive Director of Macquarie Capital Markets Canada. Most recently, he was a Senior Advisor to Fort Capital Partners, a Canadian boutique investment bank.
Dr. Amanda Malone, Chief Scientific Officer and Chief Operating Officer
Dr. Amanda Malone co-founded Eupraxia Pharmaceuticals Inc. with Dr. Helliwell in 2012. She was instrumental in establishing the company's research, manufacturing, quality, non-clinical, regulatory, intellectual property, and clinical functions. Dr. Malone holds a PhD in biomedical engineering and is an inventor on six patent families that have led to over 70 patents and patent applications.
Paul Brennan, Chief Business Officer
Paul Brennan serves as the Chief Business Officer for Eupraxia Pharmaceuticals Inc.
Dr. Mark Kowalski, M.D., Pd.D., Chief Medical Officer
Dr. Mark Kowalski is the Chief Medical Officer at Eupraxia Pharmaceuticals Inc.
AI Analysis | Feedback
Clinical Trial Failure
The most critical risk for Eupraxia Pharmaceuticals is the potential for its clinical trials to fail. The company's lead product candidates, EP-104IAR and EP-104GI, are currently in Phase III and Phase II clinical trials, respectively. There is a risk that these trials may "fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development". Furthermore, trials could be "required to suspend or discontinue [...] due to side effects or other safety risks". The success of these trials is paramount to the company's future and its ability to bring any product to market.
Regulatory Approval Risk
Following successful clinical trials, Eupraxia Pharmaceuticals faces the substantial risk of not obtaining regulatory approval for its product candidates. Even with positive trial data, "future technology will require regulatory approval, which is costly and the Company may not be able to obtain it". The company may "fail to obtain regulatory approvals or only obtain approvals for limited uses or indications," which could significantly restrict market potential and profitability.
Need for Additional Financing and Capital Requirements
As a clinical-stage biotechnology company without revenue-generating products, Eupraxia Pharmaceuticals has a "limited operating history" and relies heavily on external funding to finance its extensive and costly research and development activities and clinical trials. There is a continuous "risk that additional financing [...] may not be available" when needed. Past reports have indicated concerns about its "cash burn" and cash runway, highlighting the ongoing challenge of securing sufficient capital to sustain operations and advance its pipeline.
AI Analysis | Feedback
AI Analysis | Feedback
EP-104IAR (pain relief for knee osteoarthritis)
- Global market size: USD 6.7 billion in 2024, projected to reach USD 14.3 billion by 2034.
- U.S. market size: USD 2.6 billion in 2024.
EP-104GI (eosinophilic esophagitis)
- Global market size: USD 366.2 million in 2024, projected to reach USD 5.6 billion by 2034.
- U.S. market size: USD 151.3 million in 2024.
EP-104 (other inflammatory joint conditions)
- Global arthritis market size: Approximately USD 59.0 billion in 2024 (derived from the global anti-inflammatory market where arthritis held a 48.2% share).
- U.S. arthritis market size: USD 41.77 billion in 2024.
EP-104 (benign strictures of the esophagus)
- null
EP-104 (epidural delivery)
- Global epidural and spinal anesthesia drug market size: USD 1.25 billion in 2025, projected to grow to USD 1.76 billion by 2034.
- U.S. epidural and spinal anesthesia drug market size: Approximately USD 1.0 billion in 2025 (representing over 80% of the global market).
AI Analysis | Feedback
AI Analysis | Feedback
Share Issuance
- Eupraxia Pharmaceuticals closed a public offering in February 2026, issuing 7,607,145 common shares at US$7.00 per share and 1,428,571 pre-funded warrants at US$6.99999 per pre-funded warrant, raising approximately US$63.2 million in gross proceeds.
- In September 2025, the company completed a public offering of 14,636,363 common shares at US$5.50 per share, generating approximately US$80.5 million in gross proceeds.
- A non-brokered private placement was completed in October 2024, involving the issuance of 8,905,638 Series 1 Preferred shares at C$5.00 per share, resulting in aggregate gross proceeds of C$44,528,190.
Inbound Investments
- Eupraxia Pharmaceuticals completed a non-brokered private placement in October 2024, raising C$44.5 million from Series 1 Preferred shares. In connection with this private placement, Mr. Joseph Freedman, a private equity investor, was appointed to the company's board of directors.
Capital Expenditures
- For the last 12 months, capital expenditures were approximately -$588,947.
- In the fiscal year 2023, capital expenditures amounted to $99.03K.
- The company indicates that proceeds from recent offerings may be used, in part, for capital expenditures, alongside general corporate and administrative expenses, to support future growth and intellectual property expansion.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 15.4% | 55.7% | 98.5% | CAH 471% · MCK 396% · COR 189% |
| Health Care Services | 20 | 19.4% | 46.6% | 16.2% | HIMS 284% · RDNT 123% · DGX 83% |
| Health Care Facilities | 24 | 1.1% | 19.2% | 5.8% | NHC 289% · THC 283% · ENSG 150% |
| Managed Health Care | 8 | 39.7% | 2.1% | 3.2% | OSCR 96% · HQY 49% · ELV 11% |
| Health Care Equipment | 50 | -3.1% | 6.3% | -12.6% | UFPT 374% · GKOS 293% · TMDX 163% |
| Pharmaceuticals | 61 | -11.9% | 5.1% | -33.1% | LQDA 1006% · KNSA 654% · CORT 474% |
| Health Care Supplies | 11 | 20.8% | -3.2% | -38.6% | LNTH 341% · HAE 62% · MMSI 30% |
| Life Sciences Tools & Services | 109 | -10.1% | -10.2% | -67.3% | MEDP 250% · NTRA 249% · IRTC 76% |
| Biotechnology ← | 364 | -22.7% | -23.5% | -80.8% | DNTH 1103% · ELVN 1075% · TRVI 961% |
| Health Care Technology | 22 | -26.5% | -63.2% | -82.3% | VEEV 1% · DOCS -48% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 5.42 |
| Mkt Cap | 0.1 |
| Rev LTM | 0 |
| Op Inc LTM | -11 |
| FCF LTM | -9 |
| FCF 3Y Avg | -5 |
| CFO LTM | -9 |
| CFO 3Y Avg | -5 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.4% |
| Rev Chg 3Y Avg | 7.4% |
| Rev Chg Q | 10.6% |
| QoQ Delta Rev Chg LTM | 2.6% |
| Op Inc Chg LTM | -95.9% |
| Op Inc Chg 3Y Avg | -18.0% |
| Op Mgn LTM | 18.2% |
| Op Mgn 3Y Avg | 11.6% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 12.5% |
| CFO/Rev 3Y Avg | 9.9% |
| FCF/Rev LTM | 10.0% |
| FCF/Rev 3Y Avg | 7.7% |
Price Behavior
| Market Price | $7.59 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 08/03/2021 | |
| Distance from 52W High | -16.6% | |
| 50 Days | 200 Days | |
| DMA Price | $7.56 | $7.34 |
| DMA Trend | up | up |
| Distance from DMA | 0.3% | 3.4% |
| 3M | 1YR | |
| Volatility | 78.7% | 66.6% |
| Downside Capture | 111.04 | 161.94 |
| Upside Capture | 164.38 | 159.97 |
| Correlation (S&P 500) | 20.8% | 29.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.06 | 1.24 | 1.27 | 1.38 | 1.46 | 0.69 |
| Up Beta | -8.30 | -0.41 | 1.76 | 1.47 | 1.39 | 0.35 |
| Down Beta | 5.60 | 3.65 | 1.66 | 1.87 | 1.48 | 0.65 |
| Up Capture | 477% | 277% | 182% | 134% | 228% | 77% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 12 | 25 | 34 | 65 | 124 | 307 |
| Down Capture | -116% | -56% | -5% | 114% | 121% | 98% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 10 | 17 | 30 | 61 | 125 | 326 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EPRX | |
|---|---|---|---|---|
| EPRX | 38.4% | 66.6% | 0.74 | - |
| Sector ETF (XLV) | 26.6% | 16.3% | 1.26 | 8.1% |
| Equity (SPY) | 14.8% | 12.7% | 0.80 | 29.2% |
| Gold (GLD) | -2.2% | 28.4% | -0.09 | 31.0% |
| Commodities (DBC) | 52.1% | 20.7% | 1.91 | -0.4% |
| Real Estate (VNQ) | 4.7% | 13.9% | 0.08 | 9.9% |
| Bitcoin (BTCUSD) | -22.4% | 43.4% | -0.47 | 13.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EPRX | |
|---|---|---|---|---|
| EPRX | 4.7% | 71.6% | 0.42 | - |
| Sector ETF (XLV) | 9.0% | 15.3% | 0.39 | 11.3% |
| Equity (SPY) | 13.0% | 17.1% | 0.57 | 15.8% |
| Gold (GLD) | 17.1% | 18.9% | 0.72 | 14.1% |
| Commodities (DBC) | 9.3% | 19.5% | 0.36 | 0.2% |
| Real Estate (VNQ) | 1.1% | 18.9% | -0.05 | 14.6% |
| Bitcoin (BTCUSD) | 8.0% | 51.7% | 0.33 | 8.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EPRX | |
|---|---|---|---|---|
| EPRX | 2.3% | 71.6% | 0.42 | - |
| Sector ETF (XLV) | 11.8% | 16.7% | 0.58 | 11.3% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 15.8% |
| Gold (GLD) | 11.9% | 16.4% | 0.59 | 14.1% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 0.2% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.21 | 14.6% |
| Bitcoin (BTCUSD) | 63.0% | 66.2% | 1.03 | 8.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Investor Activity (13F)
Updated Oct 23, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.